NCT02384512

Brief Summary

End-of-dose fluctuations e. g. wearing-off are defined as a recurrence of motor and non-motor Parkinson's Disease (PD) symptoms that precedes a scheduled dose and improves with the next dose of anti-parkinsonian medication. Azilect® is approved and recommended for therapy of wearing-off-/End-of-dose fluctuations and improves motor fluctuations significantly in combination therapy with L-dopa and other parkinsonian medication.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
261

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2014

Shorter than P25 for all trials

Geographic Reach
1 country

140 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2014

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2014

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2015

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

March 4, 2015

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 10, 2015

Completed
Last Updated

April 12, 2023

Status Verified

April 1, 2023

Enrollment Period

11 months

First QC Date

March 4, 2015

Last Update Submit

April 11, 2023

Conditions

Keywords

Parkinson's diseaseakinesiaAzilect®RasagilineCombination therapy with L-dopaWearing-off Questionnaire-32Quality of lifeDaily practice

Outcome Measures

Primary Outcomes (1)

  • Wearing-off Questionnaire-32 (WOQ-32)

    Alterations of 32 different wearing-off symptoms (Patient questionnaire)

    12 weeks

Secondary Outcomes (5)

  • WHO-5

    12 weeks

  • GI-I

    12 weeks

  • Columbia University Rating Scale (CURS)

    12 weeks

  • Clinical global impression improvement (CGI-I)

    12 weeks

  • Percentage of participants with adverse events

    12 weeks

Interventions

AZILECT® 1mg Tablets

Also known as: Rasagiline

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Participants will be patients with Parkinson's disease in Germany

You may qualify if:

  • idiopathic Parkinson's disease based on the UK Brain Bank criteria,
  • Wearing-off / end-of-dose akinesia
  • at least 18 years old,
  • written consent to participate in the study.

You may not qualify if:

  • contraindications according to the SmPC of Azilect®,
  • treatment with Azilect® in the past 3 months and / or
  • suffering from a relevant cognitive impairment and therefore neither understand the patient information, nor can give their consent to participate.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (140)

Teva Investigational Sites

Aalen, Germany

Location

Teva Investigational Sites

Achim, Germany

Location

Teva Investigational Sites

Altenburg, Germany

Location

Teva Investigational Sites

Altenholz, Germany

Location

Teva Investigational Sites

Alzenau in Unterfranken, Germany

Location

Teva Investigational Sites

Apolda, Germany

Location

Teva Investigational Sites

Aschaffenburg, Germany

Location

Teva Investigational Sites

Bad Honnef, Germany

Location

Teva Investigational Sites

Bad Kissingen, Germany

Location

Teva Investigational Sites

Bad Mergentheim, Germany

Location

Teva Investigational Sites

Bad Schwartau, Germany

Location

Teva Investigational Sites

Bad Waldsee, Germany

Location

Teva Investigational Sites

Bad Wörishofen, Germany

Location

Teva Investigational Sites

Bensheim, Germany

Location

Teva Investigational Sites

Bergisch Gladbach, Germany

Location

Teva Investigational Sites

Berlin, Germany

Location

Teva Investigational Sites

Bernburg, Germany

Location

Teva Investigational Sites

Bielefeld, Germany

Location

Teva Investigational Sites

Bochum, Germany

Location

Teva Investigational Sites

Bockhorn, Germany

Location

Teva Investigational Sites

Bogen, Germany

Location

Teva Investigational Sites

Bonn, Germany

Location

Teva Investigational Sites

Butzbach, Germany

Location

Teva Investigational Sites

Buxtehude, Germany

Location

Teva Investigational Sites

Chemnitz, Germany

Location

Teva Investigational Sites

Cloppenburg, Germany

Location

Teva Investigational Sites

Cologne, Germany

Location

Teva Investigational Sites

Cottbus, Germany

Location

Teva Investigational Sites

Dessau, Germany

Location

Teva Investigational Sites

Dillingen, Germany

Location

Teva Investigational Sites

Düsseldorf, Germany

Location

Teva Investigational Sites

Eisleben Lutherstadt, Germany

Location

Teva Investigational Sites

Erbach im Odenwald, Germany

Location

Teva Investigational Sites

Erfurt, Germany

Location

Teva Investigational Sites

Essen, Germany

Location

Teva Investigational Sites

Flensburg, Germany

Location

Teva Investigational Sites

Frankfurt, Germany

Location

Teva Investigational Sites

Fürth, Germany

Location

Teva Investigational Sites

Gadebusch, Germany

Location

Teva Investigational Sites

Gelsenkirchen, Germany

Location

Teva Investigational Sites

Gera, Germany

Location

Teva Investigational Sites

Gladenbach, Germany

Location

Teva Investigational Sites

Göppingen, Germany

Location

Teva Investigational Sites

Göttingen, Germany

Location

Teva Investigational Sites

Greifswald, Germany

Location

Teva Investigational Sites

Großbeeren, Germany

Location

Teva Investigational Sites

Grünstadt, Germany

Location

Teva Investigational Sites

Hagen, Germany

Location

Teva Investigational Sites

Halsbrücke, Germany

Location

Teva Investigational Sites

Hamburg, Germany

Location

Teva Investigational Sites

Hanover, Germany

Location

Teva Investigational Sites

Heidenheim, Germany

Location

Teva Investigational Sites

Herne, Germany

Location

Teva Investigational Sites

Hettstedt, Germany

Location

Teva Investigational Sites

Hildesheim, Germany

Location

Teva Investigational Sites

Hoppegarten, Germany

Location

Teva Investigational Sites

Ilmenau, Germany

Location

Teva Investigational Sites

Immenstadt im Allgäu, Germany

Location

Teva Investigational Sites

Iserlohn, Germany

Location

Teva Investigational Sites

Itzehoe, Germany

Location

Teva Investigational Sites

Jülich, Germany

Location

Teva Investigational Sites

Kaiserslautern, Germany

Location

Teva Investigational Sites

Karlstadt am Main, Germany

Location

Teva Investigational Sites

Kastellaun, Germany

Location

Teva Investigational Sites

Katzenelnbogen, Germany

Location

Teva Investigational Sites

Kaufbeuren, Germany

Location

Teva Investigational Sites

Kempten, Germany

Location

Teva Investigational Sites

Kiel, Germany

Location

Teva Investigational Sites

Kleve, Germany

Location

Teva Investigational Sites

Königsbrück, Germany

Location

Teva Investigational Sites

Krefeld, Germany

Location

Teva Investigational Sites

Ladenburg, Germany

Location

Teva Investigational Sites

Landshut, Germany

Location

Teva Investigational Sites

Lappersdorg, Germany

Location

Teva Investigational Sites

Lauf, Germany

Location

Teva Investigational Sites

Leer, Germany

Location

Teva Investigational Sites

Leipzig, Germany

Location

Teva Investigational Sites

Leverkusen, Germany

Location

Teva Investigational Sites

Limburg, Germany

Location

Teva Investigational Sites

Lingen, Germany

Location

Teva Investigational Sites

Lohr, Germany

Location

Teva Investigational Sites

Ludwigshafen, Germany

Location

Teva Investigational Sites

Magdeburg, Germany

Location

Teva Investigational Sites

Mainz, Germany

Location

Teva Investigational Sites

Mannheim, Germany

Location

Teva Investigational Sites

Markkleeberg, Germany

Location

Teva Investigational Sites

Menden, Germany

Location

Teva Investigational Sites

Mittweida, Germany

Location

Teva Investigational Sites

Mönchengladbach, Germany

Location

Teva Investigational Sites

Mühlhausen, Germany

Location

Teva Investigational Sites

München, Germany

Location

Teva Investigational Sites

Naumburg, Germany

Location

Teva Investigational Sites

Neu-Ulm, Germany

Location

Teva Investigational Sites

Neuburg am Inn, Germany

Location

Teva Investigational Sites

Neunkirchen, Germany

Location

Teva Investigational Sites

Neupotz, Germany

Location

Teva Investigational Sites

Neusäß, Germany

Location

Teva Investigational Sites

Nuremberg, Germany

Location

Teva Investigational Sites

Oberhausen, Germany

Location

Teva Investigational Sites

Oldenburg, Germany

Location

Teva Investigational Sites

Osnabrück, Germany

Location

Teva Investigational Sites

Ostfildern, Germany

Location

Teva Investigational Sites

Pulheim, Germany

Location

Teva Investigational Sites

Ravensburg, Germany

Location

Teva Investigational Sites

Regensburg, Germany

Location

Teva Investigational Sites

Ribnitz-Damgarten, Germany

Location

Teva Investigational Sites

Rostock, Germany

Location

Teva Investigational Sites

Rotenburg (Wümme), Germany

Location

Teva Investigational Sites

Saalouis, Germany

Location

Teva Investigational Sites

Sande, Germany

Location

Teva Investigational Sites

Schirgiswalkde-Kirschau, Germany

Location

Teva Investigational Sites

Schleiden, Germany

Location

Teva Investigational Sites

Schongau, Germany

Location

Teva Investigational Sites

Schwarzenbruck, Germany

Location

Teva Investigational Sites

Schweich, Germany

Location

Teva Investigational Sites

Schweinfurt, Germany

Location

Teva Investigational Sites

Schwerin, Germany

Location

Teva Investigational Sites

Schwetzingen, Germany

Location

Teva Investigational Sites

Seelow, Germany

Location

Teva Investigational Sites

Siegen, Germany

Location

Teva Investigational Sites

Sinsheim, Germany

Location

Teva Investigational Sites

Solingen, Germany

Location

Teva Investigational Sites

Sondershausen, Germany

Location

Teva Investigational Sites

Sprockhövel, Germany

Location

Teva Investigational Sites

Stade, Germany

Location

Teva Investigational Sites

Stralsund, Germany

Location

Teva Investigational Sites

Stuttgart, Germany

Location

Teva Investigational Sites

Treuenbrietzen, Germany

Location

Teva Investigational Sites

Troisdorg-Sieglar, Germany

Location

Teva Investigational Sites

Tübingen, Germany

Location

Teva Investigational Sites

Ulm, Germany

Location

Teva Investigational Sites

Varel, Germany

Location

Teva Investigational Sites

Vellmar, Germany

Location

Teva Investigational Sites

Weißenfels, Germany

Location

Teva Investigational Sites

Wismar, Germany

Location

Teva Investigational Sites

Wolfach, Germany

Location

Teva Investigational Sites

Wolfratshausen, Germany

Location

Teva Investigational Sites

Wuppertal, Germany

Location

Teva Investigational Sites

Zossen, Germany

Location

Teva Investigational Sites

Zwickau, Germany

Location

MeSH Terms

Conditions

Parkinson Disease

Interventions

rasagiline

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Study Officials

  • Medical Expert, MD

    Paracelsus Elena Klinik

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 4, 2015

First Posted

March 10, 2015

Study Start

January 1, 2014

Primary Completion

December 1, 2014

Study Completion

January 1, 2015

Last Updated

April 12, 2023

Record last verified: 2023-04

Locations